Craig K from Seeking Alpha is long here and noted the stock down a buck when he wrote on ACUR.
However, you can add another - .40, so since 3.60's down more like $1.40 per share. His article lacked any real in depth DD and mentions the stock could improve "IF" insiders start seeing revenues from what they claim to be national wholesaler agreements for their product.
Personally, I don't know why SA authors bother to write what we already know through some elementary DD. I'd rather not hear from anyone who calls themselves a pro investor, if all they have to offer is grade school homework.
SA author was trying to rationalize otherwise puzzling behavior of insiders. What DD could he possibly write? Jones and Co are such amateurs that nobody knows what these guys are doing or thinking. For example, I am now inclined to believe that $75MM of recent shelf filling WILL NOT be used for any development, promotions etc. of Nexafed but rather as a poison pill if somebody decides to buy ACUR. As soon as stock price jumped, appeared on CNBC, everybody got excited, etc. insiders rushed to announce $75MM shelf filling, eventhough the company has a healthy $29MM in cash reserves. No sane CEO or board would approve such thing, unless the objective is to crush the stock price and proceed with their glacier speed strategy.
It is as if insiders want for ACUR stock to be below radar screen.
BTW, insiders hold only 23% of shares. We need to alert the major shareholders about this, and demand replacement of management.